Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

НАРУШЕНИЕ ВСАСЫВАНИЯ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЖИРОРАСТВОРИМЫХ ВИТАМИНОВ ПРИ БОЛЕЗНЯХ ПЕЧЕНИ

Полный текст:

Аннотация

В обзорной статье рассматриваются вопросы эффективности и тактики назначения жирорастворимых витаминов, как при холестатических, так и нехолестатических болезнях печени, а также водорастворимых витаминов, в частности, витамина С при желчнокаменной болезни. Окислительный стресс, в результате хронического воспаления является одним из основных механизмов преобразования фиброза печени в цирроз. Дисбаланс между продукцией реактивных форм кислорода и антиоксидантной защитой вызывает ряд патофизиологических изменений в печени, в том числе активацию печеночных звездчатых клеток. У носителей I148M мутации в PNPLA3 не наблюдалось уменьшения концентрации в печени витамина А с увеличением тяжести заболевания, но отмечалось снижение уровня циркулирующего ретинил пальмитата и ретинол-связывающего белка. К назначению витамина А при болезнях печени следует подходить с осторожностью. Гипервитаминоз А приводит к ускоренному фиброзу печени и стимулирует канцерогенез. В настоящее время активно изучается возможность использования витамина Е, как антиоксиданта, у больных с неалкогольной жировой болезнью печени. Его присутствие в мембранах фосфолипидного бислоя клеток позволяет предотвратить окисление неферментативных компонентов клеток свободными радикалами. Витамин Е может подавлять профибротические процессы. У пациентов с хроническими холестатическими заболеваниями печени распространена недостаточность витамина K, даже при его назначении, и связана со степенью холестаза и тяжестью заболевания. Гиповитаминоз D при болезнях печени также связан с тяжестью заболевания: коррелирует с выраженностью печеночной недостаточности и инфекционными осложнениями. Витамин D является независимым прогностическим параметром риска смертности у пациентов с циррозом печени.

Об авторах

А. И. Хавкин
Научно-исследовательский клинический институт педиатрии Российского национального исследовательского медицинского университета им. Н.И. Пирогова
Россия


О. Н. Комарова
Научно-исследовательский клинический институт педиатрии Российского национального исследовательского медицинского университета им. Н.И. Пирогова
Россия


Список литературы

1. Sharma A., Aggarwal S., Sharma V. Bitot’s Spots: Look at the Gut. Int J Prev Med. 2014 Aug; 5(8):1058-1059.

2. Herring W1, Nowicki MJ, Jones JK An uncommon cause of esophagitis. Answer to the clinical challenges and images in GI question: image 1: esophageal hyperkeratosis secondary to vitamin A deficiency. Gastroenterology. 2010 Aug;139(2):e6-7. doi: 10.1053/ j.gastro.2009.09.074. Epub 2010 Jun 25.

3. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-72. doi: 10.1152/physrev.00013.2007.

4. Pappa HM, Bern E, Kamin D, Grand RJ Curr Vitamin D status in gastrointestinal and liver disease. Opin Gastroenterol. 2008 Mar;24(2):176-83.

5. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81

6. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003; 22(2):142-6.

7. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387-91.

8. Vieth R, Kimball S, Hu A, et al. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J.2004;3:8.

9. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes FaNB, Institute of Medicine. The National Academies Press; 1997.

10. Bruno RS, Leonard SW, Park SI, Zhao Y, Traber MG. Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled α-tocopheryl acetate. Am J Clin Nutr. 2006;83(2):299-304.

11. Traber MG. Vitamin E. In: Erdman JWJ, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition. 10th ed. Washington, D. C.: Wiley-Blackwell; 2012:214-229.

12. Traber MG. Vitamin E. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2014:293-304.

13. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood, 1999, 93(6):1798-808]

14. Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C. The role of menaquinones (vitamin K(2)) in human health. Br J Nutr. 2013; 110(8):1357-1368.

15. Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev. 2012;26(1):1-14.

16. Kramps M, Flanagan A, Smaldone A. The use of vitamin K supplementation to achieve INR stability: a systematic review and meta-analysis. J Am Assoc Nurse Pract. 2013;25(10):535-544.

17. Lam J, Schulman S, Witt DM, Vandvik PO, Qayyum F, Holbrook AM. Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy. 2013;33(11):1184-1190.

18. Mahtani KR, Heneghan CJ, Nunan D, Roberts NW. Vitamin K for improved anticoagulation control in patients receiving warfarin. Cochrane Database Syst Rev. 2014;5: CD009917.

19. Ha HL, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol. 2010; 16(48):6035-43.

20. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1):125-72.

21. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014; 23(15):4077-85.

22. Mondul A, Mancina RM, Merlo A, Dongiovanni P, Rametta R, Montalcini T, et al. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr.2015; 145(8):1687-91.

23. Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis. 2013;45(8):619-24.

24. Chaves GV, Peres WA, Gonçalves JC, Ramalho A. Vitamin A and retinol-binding protein deficiency among chronic liver disease patients. Nutrition. 2015 May; 31(5):664-8. 2014.

25. Nollevaux MC, Guiot Y, Horsmans Y, Leclercq I, Rahier J, Geubel AP, Sempoux C. Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int. 2006 Mar; 26(2):182-6.

26. Yachana Kataria, Ryan J. Deaton, Erika Enk, Ming Jin, Milita Petrauskaite, Linlin Dong, Joseph R. Goldenberg, Scott J. Cotler, Donald M. Jensen, Richard B. van Breemen, and Peter H. Gann. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016; 16:30.

27. Arantes Ferreira Peres W, Villaça Chaves G, Saraiva Gonçalves JC, Ramalho A, Moraes Coelho HS. Assessment of the relative dose-response test as indicators of hepatic vitamin A stores in various stages of chronic liver disease. Nutr Clin Pract. 2013 Feb; 28(1):95-100.

28. Newsome PN1, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, Plevris JN. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther. 2000 Oct; 14(10):1295-301.

29. Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308:267-270.

30. Houglum K, Venkataramani A, Lyche K, et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113:1069-1073.

31. Morante M, Sandoval J, Gomez-Cabrera MC, et al. Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes. Free Radic Res 2005; 39:1127-1138.

32. Soden JS, Devereaux MW, Haas JE, et al. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology 2007; 46:485-495.

33. Sokol RJ, McKim JM, Jr, Goff MC, et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 1998; 114:164-174.

34. Timothy Hardy, Quentin M. Anstee, and Christopher P. Day Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015 May; 31(3): 175-183.

35. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685.

36. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. J Am Med Assoc 2011; 305:1659-1668.

37. Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010; 341: c5702.

38. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46.

39. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 1996 Jul; 16(7):3410-9.

40. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut 2011; 60:1278-1283.

41. Strople J, Lovell G, Heubi J.J Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. Pediatr Gastroenterol Nutr. 2009 Jul; 49(1):78-84.

42. Mager DR, McGee PL, Furuya KN, Roberts EA Prevalence of vitamin K deficiency in children with mild to moderate chronic liver disease. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):71-6.

43. Применение гепатопротективной терапии при лечении хронических заболеваний и поражений печени (методические рекомендации). Под общей ред. А. Л. Ракова. М., 2006. 22 с.

44. Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol. 1999 Oct;14(10):1034-40.

45. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol. 2000; 95(9):2343-51.

46. Argao EA, Balistreri WF, Hollis BW, et al. Effect of orthotopic liver transplantation on bone mineral content and serum vitamin D metabolites in infants and children with chronic cholestasis. Hepatology.1994;20(3):598-603.

47. Floreani A, Carderi I, Ferrara F, et al. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis. 2007;39(6):544-8.

48. Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012; 57:897-909.

49. Stokes CS, Krawczyk M, Reichel C, Lammert F, Grünhage F. Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. Eur J Clin Invest. 2014 Feb; 44(2):176-83.

50. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551-1561.

51. Finkelmeier F, Kronenberger B, Zeuzem S, Piiper A, Waidmann O. Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis PLoS One. 2015 Jun 29; 10(6): e0132119.

52. Alan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310-1324.

53. Han YP, Kong M, Zheng S, Ren Y, Zhu L, Shi H, et al. Vitamin D in liver diseases: from mechanisms to clinical trials. J Gastroenterol Hepatol. 2013; 28:49-55.

54. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes.Cytokine 2009;45:190-197.

55. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59:583-594.

56. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35:217-224.

57. Assa A, Vong L, Pinnell LJ, Avitzur N, Johnson-Henry KC, Sherman PM. Vitamin D Deficiency Promotes Epithelial Barrier Dysfunction and Intestinal Inflammation. J Infect Dis. 2014;210:1296-1305.

58. Trépo E, Ouziel R, Pradat P, Momozawa Y, Quertinmont E, Gervy C, et al. Marked 25-hydroxvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol2013; 59:344-350.

59. Shen YM, Wu JF, Hsu HY, Ni YH, Chang MH, Liu YW, Lai HS, Hsu WM, Weng HL, Chen HL. Oral absorbable fat-soluble vitamin formulation in pediatric patients with cholestasis. J Pediatr Gastroenterol Nutr. 2012 Nov; 55(5):587-91].

60. Veena L. Venkat, MD, Benjamin L. Shneider, MD et al. Total Serum Bilirubin Predicts Fat-Soluble Vitamin Deficiency Better Than Serum Bile Acids in Infants with Biliary Atresia. J Pediatr Gastroenterol Nutr. 2014 Dec; 59(6): 702-707.

61. Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalence among US adults: the Third National Health and Nutrition Examination Survey (NHANES III). Arch Intern Med. 2000; 160(7):931-936.

62. Duane WC, Hutton SW. Lack of effect of experimental ascorbic acid deficiency on bile acid metabolism, sterol balance, and biliary lipid composition in man. J Lipid Res. 1983; 24:1186-1195.

63. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005;41:1138-1143.

64. Simon JA, Grady D, Snabes MC, Fong J, Hunninghake DB. Ascorbic acid supplement use and the prevalence of gallbladder disease. Heart & Estrogen-Progestin Replacement Study (HERS) Research Group. J Clin Epidemiol. 1998; 51:257-265.

65. Walcher T1, Haenle MM, Kron M, Hay B, Mason RA, Walcher D, Steinbach G, Kern P, Piechotowski I, Adler G, Boehm BO, Koenig W, Kratzer W. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterol. 2009 Oct 8;9:74.

66. Leitzmann MF, Rimm EB, Willett WC, Spiegelman D, Grodstein F, Stampfer MJ, Colditz GA, Giovannucci E. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med. 1999; 341:777-784.


Для цитирования:


Хавкин А.И., Комарова О.Н. НАРУШЕНИЕ ВСАСЫВАНИЯ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЖИРОРАСТВОРИМЫХ ВИТАМИНОВ ПРИ БОЛЕЗНЯХ ПЕЧЕНИ. Экспериментальная и клиническая гастроэнтерология. 2016;(7):86-94.

For citation:


Khavkin A.I., Komarova O.N. MALABSORPTION FAT-SOLUBLE VITAMINS AND PROSPECTS OF THEIR USE IN LIVER DISEASES. Experimental and Clinical Gastroenterology. 2016;(7):86-94. (In Russ.)

Просмотров: 290


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)